A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Or Metastatic Mtap-deleted
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Have a documented STK11 mutation in a solid tumor
    2. 2) Have confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Been currently participating in or has planned participation in a study of another investigational agent or device
    2. 2) Known allergy, hypersensitivity, or intolerance to


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.